The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://gerardaiuu593847.daneblogger.com/37834988/glp-3-retatrutide-a-comparative-analysis